Skip to main content
VivoSim Labs, INC. logo

VivoSim Labs, INC. — Investor Relations & Filings

Ticker · VIVS ISIN · US68620A2033 US Professional, scientific and technical activities
Open in API
Filings indexed 790 across all filing types
Latest filing 2022-07-08 Director's Dealing
Country US United States of America
Listing US VIVS

About VivoSim Labs, INC.

https://organovo.com/

VivoSim Labs, Inc. is a biotechnology services company that develops and utilizes bioprinted, three-dimensional (3D) human tissues designed to emulate human biology and disease. The company provides testing services for drugs and drug candidates, primarily for the pharmaceutical and biotechnology sectors. VivoSim Labs specializes in offering liver and intestinal toxicology insights through its proprietary New Approach Methodologies (NAMs), including its NAMkind™ 3D models. These non-animal testing platforms are used to generate human-relevant safety and toxicology data early in the drug discovery and development process, aiming to provide insights before animal studies or clinical trials.

Recent filings

Filing Released Lang Actions
FORM 5 SUBMISSION
Director's Dealing
2022-07-08 English
10-K
Annual Report FY 2022
2022-06-10 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-10 English
FORM 3 SUBMISSION
Director's Dealing
2022-03-10 English
8-K
Board/Management Information Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 8, 2022, by Organovo Holdings, Inc. The content focuses on the appointment of a new director to the Board of Directors, including details about the director's background, compensation, and indemnification agreement. There is no financial data or report content, but rather an announcement of a change in the company's board. This matches the description for Board/Management Information filings (MANG). The document length is about 5978 characters, which is sufficient for a detailed announcement but does not contain financial statements or earnings data. Therefore, the correct classification is MANG with high confidence.
2022-03-10 English
8-K
Legal Proceedings Report Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a settlement and patent license agreement between Organovo Holdings, Inc. and BICO Group AB, including details of patent litigation and the terms of the settlement. It also references a press release attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this an earnings release or annual report. The document is primarily an announcement of a material definitive agreement and related legal settlement. According to the filing definitions, such announcements of material agreements and legal settlements are best classified under Legal Proceedings Report (LTR). The document is not a full legal proceeding report but is a significant legal update related to patent litigation and settlement, fitting the LTR category better than others. Therefore, the classification is LTR with high confidence.
2022-02-28 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.